This website is intended for healthcare professionals only.

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Oncology

Broadened marketing authorisation for Darzalex in multiple myeloma recommended
Broadened marketing authorisation for Darzalex in multiple myeloma recommended
First biosimilar mAb in oncology is granted EU marketing authorisation
First biosimilar mAb in oncology is granted EU marketing authorisation
SMC accepts six new medicines for routine use in NHS Scotland
SMC accepts six new medicines for routine use in NHS Scotland
Tagrisso demonstrates superiority over chemotherapy in mutation-positive NSCLC
Tagrisso demonstrates superiority over chemotherapy in mutation-positive NSCLC
EU approval of Teva’s Trisenox® for first line treatment of low to intermediate risk APL
EU approval of Teva’s Trisenox® for first line treatment of low to intermediate risk APL
Lymphoseek may be alternative to elective neck dissection to stage oral cancer.
Lymphoseek may be alternative to elective neck dissection to stage oral cancer
The Prostate Cancer Registry treatment outcomes data presented for the first time at ESMO 2016
The Prostate Cancer Registry treatment outcomes data presented for the first time at ESMO 2016
Automated breast ultrasound detects significantly more invasive cancers in dense breasts
Automated breast ultrasound detects significantly more invasive cancers in dense breasts
Xofigo® recommended for prostate cancer with bone metastases in an additional group
Xofigo® recommended for prostate cancer with bone metastases in an additional group
Venetoclax receives positive opinion for chronic lymphocytic leukaemia in the UK
Venetoclax receives positive opinion for chronic lymphocytic leukaemia in the UK
Janssen submits application to the EMA to expand use of daratumumab
Janssen submits application to the EMA to expand use of daratumumab
NICE draft recommendation on the use of Nexavar® (sorafenib) in liver cancer
NICE draft recommendation on the use of Nexavar® (sorafenib) in liver cancer


Popular articles

Casirivimab and imdevimab combination reduces incidence of symptomatic COVID-19
Oral upadacitinib approved by NICE for active psoriatic arthritis
Kaftrio approval for cystic fibrosis extended by EMA from 6 years of age
Smoking cessation at time of lung cancer diagnosis associated with improved survival
Neoplasia detected in a third of patients under 50 after colorectal screening




 
Hospital Healthcare Europe
 
LinkedIn Logo Footer  Twitter Logo Footer

Ⓒ Cogora 2022
Cogora Limited, 1 Giltspur Street, London EC1A 9DD, Registered in the United Kingdom. Reg. No. 2147432

Hospital Healthcare Europe
HOPE Logo Footer